Apricus Biosciences Announces Publication in Journal of Pharmaceutics and Drug Delivery Research

SAN DIEGO, Sept. 17, 2012 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. ("Apricus Bio" or the "Company") (Nasdaq:APRI) (http://www.apricusbio.com) announced today publication in the current issue of the Journal of Pharmaceutics and Drug Delivery Research of an article featuring Tolnaftate-D™, the Company's over-the-counter ("OTC") antifungal product for the treatment of Athlete's Foot. The paper, entitled "Enhancing the Skin Flux of Tolnaftate Utilizing the Novel Excipient, Dodecyl-2-N,N-Dimethylaminopropionate (DDAIP)," was written by Susan R. Meier-Davis, DVM, PhD, DABT, RAC, the Company's Vice President of Safety. The published data demonstrates that Tolnaftate-D™, Apricus Bio's novel tolnaftate formulation (tolnaftate 1% delivered using 0.5% DDAIP), resulted in a significant (57%) increase in penetration over a 24-hour period as compared to OTC tolnaftate 1%. The full article is available online at http://www.scitechnol.com/JPDDR/JPDDR-1-102.pdf.